Meeting
2024 ASCO Genitourinary Cancers Symposium
Effect of prednisone dosing on mineralocorticoid-related side effects with abiraterone in prostate cancer.
Authors
Maksym Goryachok
University of Colorado School of Medicine, Aurora, CO
Maksym Goryachok , Andrew Nicklawsky , Hiba Ahmad , Thomas W. Flaig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 67)
DOI
10.1200/JCO.2024.42.4_suppl.67
Abstract #
67
Poster Bd #
C2
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Time trends of drug specific adverse events among patients on androgen receptor antagonists: Implications for remote monitoring.
First Author: Lauren Fleshner
Poster
2024 ASCO Genitourinary Cancers Symposium
Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices.
First Author: Gordon Andrew Brown
Poster
2024 ASCO Genitourinary Cancers Symposium
(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.
First Author: Giulio Francolini
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans